SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: FTC sign above a doorway/iStock, Gromit7
Policy
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
Following a countersuit by Amgen and Horizon Therapeutics, the Federal Trade Commission has temporarily suspended its challenge to the multi-billion dollar merger between the two companies.
August 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Business
Novartis Abandons Xoma-Partnered Antibody for Pancreatic Cancer
The Swiss pharma is returning the anti-TGFβ antibody NIS793 to Xoma Corporation, from which it bought the asset in 2015 for $37 million upfront.
August 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exelixis headquarters/Company courtesy
Drug Development
Exelixis Ends Phase III Trial Early Due to ‘Dramatic’ Benefits in Neuroendocrine Tumors
Following a late-stage victory on Monday, Exelixis on Thursday reported another Phase III win for its tyrosine kinase inhibitor Cabometyx—this time in advanced neuroendocrine tumors.
August 25, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Novartis building in Switzerland
FDA
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
Amid one of the industry’s steepest patent cliffs, the regulator Thursday approved Sandoz’s Tyruko, the first biosimilar for treating relapsing multiple sclerosis in adults. Sandoz is a division of Novartis.
August 25, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
FDA
FDA Action Alert: BMS, Outlook and BiolineRx
In the next two weeks, the FDA will hand out regulatory verdicts to BMS, Outlook Therapeutics and BioLineRx.
August 24, 2023
 · 
4 min read
 · 
Tristan Manalac
Update: AbbVie headquarters building in California
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's building in Switzerland
J&J Cuts R&D at Netherlands Infectious Disease, Vaccine Unit
After slimming down its infectious diseases and vaccines business, Johnson & Johnson now appears to be ending research and development at a Dutch-based unit, except for a few programs.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: CVS Health's signage outside its office in Texas
Business
CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary
The consumer healthcare brand is joining the growing biosimilars market in the U.S. with its new subsidiary Cordavis, which will market a Humira biosimilar as its first product.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Signage outside Genentech's headquarters in Silicon Valley
Drug Development
Roche Reports Positive Phase III NSCLC Data for Anti-TIGIT Candidate After Leak
Spurred by an “inadvertent” disclosure, Roche’s Genentech on Wednesday released interim and immature overall survival findings for its anti-TIGIT antibody tiragolumab in non-small cell lung cancer.
August 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to the U.S. Department of Healt
Policy
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
Under the $1.4 billion Project NextGen initiative, Regeneron was awarded a $326 million grant for its preventive monoclonal antibody, while Johnson & Johnson got $10 million to bankroll startups.
August 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Teva Pharmaceuticals USA headquarters in
Policy
Teva to Pay $225M in DOJ Generic Drug Price-Fixing Settlement
Three years after the initial case, Teva Pharmaceuticals is finally settling its drug price-fixing charges with the Department of Justice for $225 million, payable over a five-year period.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage at its world headquarters in New York
FDA
Pfizer Wins FDA Approval for First Maternal RSV Shot to Protect Infants
The FDA on Monday gave the greenlight to Pfizer’s RSV vaccine for expectant mothers, given during the third trimester of pregnancy, designed to protect newborn babies through the first six months of life.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
External view of Boehringer Ingelheim's headquarters in Silicon Valley
Policy
Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions
The German pharmaceutical giant is the latest pharma company to challenge the constitutionality of the Inflation Reduction Act’s drug price negotiation program.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Drug Development
Roche, Exelixis’ Drug Combo Bounces Back with Late-Stage Prostate Cancer Win
After sustaining two Phase III fails, Roche and Exelixis finally reported a late-stage win for their combination regimen of Tecentriq and Cabometyx in metastatic castration-resistant prostate cancer.
August 21, 2023
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
FDA
Regeneron Expands Eylea’s Label with High-Dose Approval
Following a prior rejection due to manufacturing problems, Regeneron’s higher-dose Eylea won the FDA’s approval Friday, allowing for more infrequent dosing for the treatment of various eye diseases.
August 21, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More